Stock Events

Stock Events

Eupraxia Pharmaceuticals 

$8.40
16
+$0.90+12% Friday 20:00
+$0.05+0.6%Friday 23:33After hours

Statistics

Day High
8.4
Day Low
8.37
52W High
9.32
52W Low
5.15
Volume
19,820
Avg. Volume
-
Mkt Cap
555.02M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.37
-0.32
-0.27
-0.22
Expected EPS
-0.36654535
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-38.58MNet Income

Analyst Ratings

17.67Average Price Target
The highest estimate is 25.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EPRX. It's not an investment recommendation.
Schwab US Dividend Equity
2
SCHD
NEOS Nasdaq 100 High Income
2
QQQI
Saudi Arabian Oil Company
2
2222.SR
Rocket Lab
2
RKLB

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie competes in the pharmaceuticals sector, focusing on immunology and oncology, areas Eupraxia also targets with its drug development.
Pfizer
PFE
Mkt Cap162.16B
Pfizer is a global biopharmaceutical company with a broad range of products in various therapeutic areas, overlapping with Eupraxia's focus.
Merck
MRK
Mkt Cap370.89B
Merck operates in the pharmaceuticals industry, developing drugs that could directly compete with Eupraxia's pipeline in areas like inflammation and pain management.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its pharmaceutical segment, competes across various therapeutic areas, including those being targeted by Eupraxia.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol Myers Squibb offers a wide range of pharmaceutical products, potentially competing with Eupraxia in the development of treatments for chronic conditions.
Novartis
NVS
Mkt Cap304.1B
Novartis is a global healthcare company that operates in similar therapeutic areas as Eupraxia, making it a direct competitor in drug development.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences focuses on areas like inflammation and oncology, directly competing with Eupraxia's research and development efforts.
AMGEN
AMGN
Mkt Cap236.38B
Amgen specializes in biopharmaceuticals, with a product lineup that could compete with Eupraxia's treatments in development.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.22B
Regeneron Pharmaceuticals is involved in biopharmaceuticals, focusing on innovative treatments that could rival Eupraxia's pipeline.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.42B
Vertex Pharmaceuticals engages in creating new therapies for treating chronic diseases, a field where Eupraxia is also aiming to innovate.

About

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
Show more...
CEO
James A. Helliwell
Employees
49
Country
Canada
ISIN
CA29842P1053
WKN
000A3EGRS

Listings

F
DE
X43.F
STU
DE
X43.STU
XNAS
US
EPRX
TO
CA
EPRX.TO

0 Comments

Share your thoughts

FAQ

What is Eupraxia Pharmaceuticals stock price today?▼
The current price of EPRX is $8.40 USD — it has increased by +12% in the past 24 hours. Watch Eupraxia Pharmaceuticals stock price performance more closely on the chart.
What is Eupraxia Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Eupraxia Pharmaceuticals stocks are traded under the ticker EPRX.
Is Eupraxia Pharmaceuticals stock price growing?▼
EPRX stock has risen by +30.03% compared to the previous week, the month change is a +24.08% rise, over the last year Eupraxia Pharmaceuticals has showed a +55.84% increase.
What is Eupraxia Pharmaceuticals market cap?▼
Today Eupraxia Pharmaceuticals has the market capitalization of 555.02M
When is the next Eupraxia Pharmaceuticals earnings date?▼
Eupraxia Pharmaceuticals is going to release the next earnings report on November 11, 2026.
What were Eupraxia Pharmaceuticals earnings last quarter?▼
EPRX earnings for the last quarter are -0.22 USD per share, whereas the estimation was -0.22 USD resulting in a +1.35% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Eupraxia Pharmaceuticals revenue for the last year?▼
Eupraxia Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Eupraxia Pharmaceuticals net income for the last year?▼
EPRX net income for the last year is -38.58M USD.
How many employees does Eupraxia Pharmaceuticals have?▼
As of September 07, 2026, the company has 49 employees.
In which sector is Eupraxia Pharmaceuticals located?▼
Eupraxia Pharmaceuticals operates in the Health & Wellness sector.
When did Eupraxia Pharmaceuticals complete a stock split?▼
Eupraxia Pharmaceuticals has not had any recent stock splits.
Where is Eupraxia Pharmaceuticals headquartered?▼
Eupraxia Pharmaceuticals is headquartered in Victoria, Canada.